How we improved the treatment of Hodgkin lymphoma

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

July 18, 2025

Vol.51 No.28

By Jeff Sorenson

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.

July 11, 2025

Vol.51 No.27

Podcast

In The Headlines: George Weiner on the importance of patients’ stories

In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.

July 09, 2025

Vol.51 No.26

How we improved the treatment of Hodgkin lymphoma

YOU MAY BE INTERESTED IN

City of Hope brings evidence-based approaches to integrative oncology

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

Imaging’s ride to the bottom in clinical trials—and why it matters now

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

In The Headlines: George Weiner on the importance of patients’ stories

Renew today!

Subscriber content

Never miss an issue!

Login